AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04618497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
Study NCT04618497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
Study NCT01748448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: * prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening
Study NCT01748448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arachides oleum raffinatum
Study NCT03871881 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: A special designed neuropsychological test battery of validated tests to assess function of cognitive domains
Study NCT03407391 — intervention group
Intervention type: OTHER
Intervention: None - observational
Description: No intervention - observational only
Study NCT01825044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSTAT 5 mg/kg/day
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
Study NCT01825044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSTAT 10 mg/kg/day
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
Study NCT00916799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Telehealth equipment (Viterian V-100)
Description: Patient will daily enter answers to questions generated from a home telehealth monitor
Study NCT03907735 — intervention group
Intervention type: OTHER
Intervention: Myometrial tissue sample collection
Description: Myometrial tissue samples by core needle biopsy under ultrasound guidance
Study NCT04510922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa 100 MG [Northera]
Description: droxidopa taken three times a day titrated up to a maximum of 600 mg.
Study NCT01411293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Fat Milk
Description: Participants will ingest 2 cups of low-fat milk on 1 occasion.
Study NCT01411293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice Milk
Description: Participants will ingest 2 cups of rice milk on 1 occasion.
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat-based support
Description: Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD plus COVID-specific advice
Description: Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 related health warning leaflet
Description: The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-based support
Description: Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.
Study NCT04399967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH Self-help smoking cessation booklet
Description: A general smoking cessation self-help booklet
Study NCT00175006 — intervention group
Intervention type: OTHER
Intervention: Measurement of Tophi to validate procedure
Description: Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
Study NCT01302041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT04175197 — intervention group
Intervention type: DEVICE
Intervention: Drug Coated Balloon
Description: Legflow Drug Coated Balloon
Study NCT04196842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring devices
Description: Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
Study NCT01348178 — intervention group
Intervention type: PROCEDURE
Intervention: Follow-up
Description: Follow-up
Study NCT03065673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium oxalate 5% gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT03065673 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT01447173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
Study NCT01447173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
Study NCT02225223 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: STAR™ Tumor Ablation System
Description: Targeted-radiofrequency ablation (t-RFA)
Study NCT02225223 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: StabiliT® Vertebral Augmentation System
Description: Radiofrequency-targeted vertebral augmentation (RF-TVA)
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perjeta Injectable Product
Description: Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta Injectable Product
Description: Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Study NCT01476579 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Computer Tomography
Description: Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
Study NCT01446029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Telemonitoring Device with Clinical Care Modules
Description: Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
Study NCT03064893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alloderm
Description: Reconstruction material
Study NCT03064893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermacell
Description: Reconstruction material
Study NCT04446975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPA
Description: At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
Study NCT02594696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Psychiatry Consultation (PPC)
Description: * The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~* The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~* The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~* The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~* Recommendations are documented in the medical record and communicated directly to the oncology team
Study NCT04218136 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
Study NCT01244009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
Study NCT02184897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenograstim 10 microgram/kg/day
Study NCT02184897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenograstim 10 microgram/kg/day
Study NCT03215225 — intervention group
Intervention type: PROCEDURE
Intervention: Root canal orthograde treatment
Study NCT02900911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation
Description: Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
Study NCT02900911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late rehabilitation
Description: Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
Study NCT01971307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SGE-PsyScan
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
Study NCT02273011 — intervention group
Intervention type: PROCEDURE
Intervention: caesarean section
Description: elective caesarean section under regional anesthesia
Study NCT01491529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)
Study NCT01491529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AFQ056 will be supplied as oral tablets.
Study NCT03308058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding computer education
Description: Breastfeeding computer education
Study NCT02647918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Single dose
Study NCT02647918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 2 single doses
Study NCT03086122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
Study NCT03318744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
Study NCT03318744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo resembling aspirin tablet will be be given to participants in control arm.
Study NCT04648306 — intervention group
Intervention type: DEVICE
Intervention: Prophylactic Impella support for a non-emergent PCI
Description: Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
Study NCT04412564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: TQ-B3101 is a ALK inhibitor.
Study NCT02613897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
Study NCT02613897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
Study NCT02613897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02083640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Formulation Reference
Description: 125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
Study NCT02083640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Formulation Test
Description: 125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
Study NCT02083640 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib Formulation Test
Description: 125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
Study NCT01192490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
Study NCT01192490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant
Description: KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
Study NCT01899560 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure lung and chest wall elastance with esophageal catheter
Description: Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated \[9\]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed.
Study NCT01899560 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-invasive method for measuring the lung elastance
Description: by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
Study NCT01744496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Patches will contain 4 mg / 24 h (20 cm\^2), 6 mg/ 24 h (30 cm\^2), or 8 mg /24 h (40 cm\^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
Study NCT01744496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.